BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:09 PM
 | 
Sep 26, 2012
 |  BC Extra  |  Top Story

BIIB's rFIXFc meets Phase III endpoints

Biogen Idec Inc. (NASDAQ:BIIB) and partner Swedish Orphan Biovitrum AB (SSE:SOBI) said rFIXFc as prophylaxis met the primary efficacy and safety endpoints in the Phase III B-LONG trial to treat hemophilia B patients. To meet the efficacy endpoint, the partners said rFIXFc as prophylaxis needed to reduce annualized bleeding rates by at least 50% compared to as needed treatment with rFIXFc for bleeding episodes. Biogen...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >